Keystone Labs Keeps OTC Drugs In Plans After Court Orders Manufacturing Halt

Keystone Labs agrees to cease manufacturing OTC drugs after repeat GMP violations following a 2013 FDA warning letter, including failure to investigate sources of contamination. Firm says it informed FDA it would outsource OTC product manufacturing and continue making hair and skin care cosmetic formulas.